@article{article, title  = {{MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/j.urolonc.2024.01.172 }},

 year = {{2024}},

 month = {{3}},

 author = {{Daneshmand S and Zaucha R and Vasdev N and Gartrell BA and Lotan Y and Hussain SA and Lee EK and Procopio G and Galanternik F and Pignot G and Sundi D et al}},

 doi = {{10.1016/j.urolonc.2024.01.172}},

 volume = {{42}},

 journal = {{Urologic Oncology: Seminars and Original Investigations}},

 pages = {{S58-S58}},

 note = {{Accessed on 2024/12/21}}}